

ASX / Media Release

7 May 2010

RHT: Resonance Health Fibrosis Results

Resonance Health Limited (ASX: RHT) today announces the result of its activities to develop a liver fibrosis measurement product using magnetic resonance imaging.

The outcome of the research has demonstrated that the technology performs well in the detection of very early stage liver fibrosis. However, it did not show sufficient competitive advantage in other fibrosis staging thresholds. More research would be required to evaluate if improvements can be gained in these areas. The Company is however, evaluating other technologies for measuring liver fibrosis and will cease further internal development until due diligence has been completed on these alternatives which may provide a better route to market.

The fibrosis development project had an additional aim to measure liver fat which also represents a significant addressable market. The outcome from this aspect of the project has been encouraging and the Company is moving forward with the development of a liver fat measurement product.

Non-alcoholic fatty liver disease affects one in five Americans and for those with diabetes the rate may be as high as four in five. Fatty liver disease has become the most common liver disease in western nations. Excess liver fat can lead to inflammation of the liver, liver fibrosis, liver cancer or even liver failure.

The gold standard for the quantification of liver fat is a liver biopsy which is invasive, painful, has inherent risks to the patient and is expensive. There is currently no other product on the market providing an accurate quantification of liver fat. Resonance Health believes this represents an attractive market to complement its existing expertise and relationships with liver specialists.

The Board will provide an update to the market on the progress of these initiatives as soon as possible.

By Order of the Board
Resonance Health Limited

For further information please contact:

Resonance Health

Liza Dunne
Managing Director
T: +61 8 9286 5300
E: lizad@ferriscan.com

Eva O'Malley
Company Secretary
T: +61 8 9286 5300
E: evao@ferriscan.com

Resonance Health Ltd (ASX: RHT) (www.resonancehealth.com) is a medical device company providing radiological image analysis services for the clinical and research communities with a strong clinical focus on the liver. Its patented technology FerriScan[®] provides a safe and accurate alternative for measuring liver iron concentration, a significant issue for patients with iron overload. The Company continues to invest in research and development into other quantitative radiological imaging technologies.